Therefore, common genomic lesions in MDS involve loss-of-function mutations in some genes, such as DNMT3A or TET2, leading to increased expression of inflammatory signalling genes and the release of pro-inflammatory molecules [8,10]. Here, DNMT3A is linked to myelodysplastic syndrome.